Drug General Information
Drug ID	D0X3TI
Former ID	DNCL002922
Drug Name	SRT3025
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 1	[523447]
Company	Sirtris
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	NAD-dependent deacetylase sirtuin-1	Target Info	Modulator	[533296]
KEGG Pathway	FoxO signaling pathway
	AMPK signaling pathway
	Glucagon signaling pathway
	Amphetamine addiction
	MicroRNAs in cancer
PANTHER Pathway	p53 pathway
Pathway Interaction Database	p73 transcription factor network
	Signaling events mediated by HDAC Class III
	E2F transcription factor network
	HIF-2-alpha transcription factor network
	Signaling events mediated by HDAC Class I
	FoxO family signaling
	Regulation of Androgen receptor activity
	Regulation of retinoblastoma protein
Reactome	RORA activates gene expression
	Regulation of HSF1-mediated heat shock response
	Circadian Clock
WikiPathways	Integrated Pancreatic Cancer Pathway
	SREBF and miR33 in cholesterol and lipid homeostasis
	Integrated Breast Cancer Pathway
	SREBP signalling
	Androgen receptor signaling pathway
References
Ref 523447	ClinicalTrials.gov (NCT01340911) A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases. U.S. National Institutes of Health.
Ref 533296	The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.